Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
69M
-
Number of holders
-
82
-
Total 13F shares, excl. options
-
31.6M
-
Shares change
-
+2.46M
-
Total reported value, excl. options
-
$275M
-
Value change
-
+$22.9M
-
Put/Call ratio
-
0.53
-
Number of buys
-
47
-
Number of sells
-
-26
-
Price
-
$8.70
Significant Holders of EyePoint Pharmaceuticals, Inc. - Common Stock (EYPT) as of Q2 2023
91 filings reported holding EYPT - EyePoint Pharmaceuticals, Inc. - Common Stock as of Q2 2023.
EyePoint Pharmaceuticals, Inc. - Common Stock (EYPT) has 82 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 31.6M shares
of 69M outstanding shares and own 45.75% of the company stock.
Largest 10 shareholders include FRANKLIN RESOURCES INC (5.06M shares), Essex Woodlands Management, Inc. (4.19M shares), SUVRETTA CAPITAL MANAGEMENT, LLC (3.42M shares), RA CAPITAL MANAGEMENT, L.P. (3.37M shares), Cormorant Asset Management, LP (3.2M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (1.78M shares), BlackRock Inc. (1.75M shares), VANGUARD GROUP INC (1.4M shares), CITADEL ADVISORS LLC (848K shares), and STATE STREET CORP (504K shares).
This table shows the top 82 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.